
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE)Â for treatment …

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …

Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …

BioAtla has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ozuriftamab vedotin, …

ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer …

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …

Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global …

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …